These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8667228)

  • 1. Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.
    Albert DH; Conway RG; Magoc TJ; Tapang P; Rhein DA; Luo G; Holms JH; Davidsen SK; Summers JB; Carter GW
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1595-606. PubMed ID: 8667228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.
    Albert DH; Magoc TJ; Tapang P; Luo G; Morgan DW; Curtin M; Sheppard GS; Xu L; Heyman HR; Davidsen SK; Summers JB; Carter GW
    Eur J Pharmacol; 1997 Apr; 325(1):69-80. PubMed ID: 9151941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist.
    Albert DH; Magoc TJ; Menacherry SD; Morgan DW; Sun E; Reyes AE; Kleinert HD; Carter GW; Summers JB
    Inflamm Res; 1997 Jul; 46(7):272-7. PubMed ID: 9266276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist.
    Kruse-Elliott KT; Albert DH; Summers JB; Carter GW; Zimmerman JJ; Grossman JE
    Shock; 1996 Apr; 5(4):265-73. PubMed ID: 8721386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
    Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
    Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist.
    Albert DH; Magoc TJ; Kleinert HD; Sun E; Reyes AE; Carter GW; Summers JB
    Adv Exp Med Biol; 1996; 416():381-7. PubMed ID: 9131177
    [No Abstract]   [Full Text] [Related]  

  • 8. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
    Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
    J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
    Ostermann G; Hofmann B; Kertscher HP; Till U
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT-299, a potent antagonist of platelet activating factor.
    Summers JB; Albert DH; Davidsen SK; Conway RG; Holms JH; Magoc TJ; Luo G; Tapang P; Rhein DA; Carter GW
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():475-7. PubMed ID: 7732895
    [No Abstract]   [Full Text] [Related]  

  • 12. ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.
    Albert DH; Luo G; Magoc TJ; Tapang P; Holms JH; Davidsen SK; Summers JB; Carter GW
    Shock; 1996 Aug; 6(2):112-7. PubMed ID: 8856845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
    Hwang SB; Li CL; Lam MH; Shen TY
    Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.
    Albert DH; Malo PE; Tapang P; Shaughnessy TK; Morgan DW; Wegner CD; Curtin ML; Sheppard GS; Xu L; Davidsen SK; Summers JB; Carter GW
    J Pharmacol Exp Ther; 1998 Jan; 284(1):83-8. PubMed ID: 9435164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor.
    Yamada T; Tomioka K; Saito M; Horie M; Mase T; Hara H; Nagaoka H
    Arch Int Pharmacodyn Ther; 1990; 308():123-36. PubMed ID: 2099131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of platelet-activating factor-receptor antagonism on endotoxin-induced lung dysfunction in sheep.
    Snapper JR; Lu W; Lefferts PL; Thabes JS
    J Appl Physiol (1985); 1998 May; 84(5):1610-4. PubMed ID: 9572806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
    J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
    Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
    J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.